Clinical TrialJul 27, 2026, 06:34 AM
Kura Oncology Darlifarnib/Cabozantinib Shows 50% Response Rate in ccRCC
AI Summary
Kura Oncology announced positive updated Phase 1a results from the FIT-001 clinical trial for darlifarnib plus cabozantinib in advanced clear cell renal cell carcinoma (ccRCC). The combination demonstrated encouraging and durable clinical activity, with response rates up to 50% and a median progression-free survival of 13 months in pre-treated, cabozantinib-naïve patients. The therapy was well tolerated, and its safety profile was consistent with individual agents, supporting continued development towards a planned registrational study in 2028.
Key Highlights
- Objective response rate up to 50% across evaluated dose levels.
- Median progression-free survival of 13 months observed.
- Results in pre-treated, cabozantinib-naïve advanced ccRCC patients.
- Combination was well tolerated with a manageable safety profile.
- Findings support darlifarnib's potential to enhance VEGFR-targeted therapies.
- Global, randomized Phase 1b study is currently underway.
- Planned registrational study for 2028 based on these findings.
Price Impact
More from KURA